Skip to content Skip to sidebar Skip to footer

All Posts

HomeAll Posts
May 22, 2026

When Light Meets GPUs: How Silicon Photonics Quietly Took Over the Data Center

Silicon photonics spent decades as the clever lab demo in search of a board‑level use case. Now, as AI data centers strain grids and mint new optics billionaires in Shenzhen and Hong Kong, that “solution in search of a problem” has finally met its moment—and its market.

From Science Project to Strategic Asset

Silicon photonics (SiPh) emerged in the 1980s, when researchers realized they could guide light through silicon and leverage the economics of CMOS fabs. For a long stretch, it lived mostly in papers, prototypes, and roadmaps, hampered by losses, integration headaches, and an industry still content to push copper a little farther every year.

The idea was beguiling: integrate lasers, modulators, and detectors alongside electronics and ship optics at semiconductor scale. But with no mass‑market pain point big enough to demand that complexity, SiPh looked like a perennial entrant in the “nice technology, call us later” category.

AI Data Centers Rewrite the Problem Statement

The rise of large AI models changed the constraint set almost overnight. Training clusters and inference farms now move astonishing volumes of data between GPUs, racks, and regions, and the traditional tools—copper plus pluggable optics—are hitting hard limits on power, reach, and complexity.

In these AI‑optimized facilities, power budgets and cooling capacity are now as central as FLOPs, and every watt burned on moving bits is a watt not available for compute. The net effect: interconnects have migrated from back‑of‑the‑deck detail to first‑page risk factor, and silicon photonics has stepped from the margins into the design center.

Silicon Photonics Becomes the Bandwidth Engine

SiPh’s killer application has turned out to be brutally practical: high‑volume optical interconnects for hyperscale and AI data centers. Silicon‑photonics‑based transceivers are already shipping in the millions into cloud and AI networks at speeds of 100G and beyond, narrowing the cost and power gap versus legacy optics while scaling more gracefully than copper.

The next leg of this evolution is co‑packaged optics, where SiPh engines sit shoulder‑to‑shoulder with switch ASICs instead of being stranded out in front‑panel modules. That tighter integration reduces power per bit, slashes reach penalties on electrical traces, and opens the door to denser, higher‑bandwidth switch systems—exactly what AI fabrics need to stitch together ever‑larger GPU clusters.

The Physics and Economics of Moving to Light

The appeal of silicon photonics is equal parts physics and economics. At modern signaling rates and the distances inside AI data centers, copper struggles with attenuation, crosstalk, and rising power for equalization and retiming; light does not. Optical links provide high bandwidth and low latency over longer reaches without a corresponding explosion in energy per bit.

Because SiPh rides on CMOS manufacturing, vendors can integrate photonic and electronic functions on compact, wafer‑scale platforms, cutting cost and improving consistency. For data‑center operators staring at multi‑year capex plans tied to AI growth, the combination of better performance and better power efficiency is less a luxury than a prerequisite to keep clusters scaling without outgrowing the local utility.

When Infrastructure Meets the Billionaire List

The macro story doesn’t end at the rack. It now shows up on rich lists and in Hong Kong IPO queues. Rising demand from AI data centers for high‑speed optical connections is driving a wave of wealth creation in the AI optics supply chain, particularly among Chinese manufacturers supplying equipment and components to global semiconductor and networking majors.

One emblematic case is RoboTechnik Intelligent Technology, a Suzhou‑based maker of assembly and testing equipment for optical systems used by customers such as Broadcom. Its Shenzhen‑listed shares surged roughly 340% over the past year, propelling founder and chairman Dai Jun’s net worth to an estimated 2.4 billion dollars and prompting the company to file for a dual listing in Hong Kong.

RoboTechnik: A Pick‑and‑Shovel Play on SiPh

RoboTechnik does not sell the photonic chips themselves; it sells the tools that help build and qualify them. The company provides assembly and testing machinery for optical systems, slotting neatly into the capital equipment layer of the AI optics value chain at precisely the time when global investment in photonic interconnects is accelerating.

The 340% rally in its Shenzhen shares reflects how investors are capitalizing on this “picks and shovels” exposure to AI data‑center capex, where demand visibility for optical interconnect and related tooling looks more durable than for any single GPU or cloud platform. By pursuing a Hong Kong dual listing, RoboTechnik aims to tap deeper pools of capital, broader investor participation, and more flexible pricing dynamics in a market that has become an active hub for AI‑linked listings.

Hong Kong as the Optics and AI Capital Magnet

RoboTechnik is not alone in looking across the border. Hong Kong has emerged as a preferred venue for Chinese AI and photonics companies seeking to raise capital and diversify their shareholder base, especially as AI optimism has fueled a broader technology rally. Mainland technology boards are trading at rich valuations, but Hong Kong offers enhanced liquidity, global investor access, and a spotlight for thematically pure AI and optics stories.

Recent listings and rallies in AI and photonics—spanning software startups, GPU players, and photonic chipmakers—underscore how investors are treating optics not as a peripheral hardware segment but as central infrastructure for the AI era. In that context, RoboTechnik’s dual‑listing ambitions look less like a one‑off and more like a template for optics‑exposed manufacturers up and down the stack.

Photonics as AI Hardware, Not Just Plumbing

Silicon photonics’ role is expanding beyond “glorified fiber drivers.” Integrated photonics is being developed as a compute engine in its own right, using light to accelerate matrix operations in AI workloads. By executing certain linear algebra tasks in the optical domain, photonic accelerators aim to improve performance per watt compared with conventional electronic hardware, particularly on inference and specialized training tasks.

Although this segment is earlier‑stage than interconnects and still carries material technology and commercialization risk, it illustrates how photonics is permeating multiple layers of the AI stack—from chip‑to‑chip links to the cores that may eventually process the models themselves. As that stack deepens, the importance of the supporting equipment ecosystem, including firms like RoboTechnik, only grows.

The New Talent and Capital Arms Race

With AI optics moving to the center of the infrastructure conversation, talent and capital are following. Demand is rising for engineers who can straddle optical physics, packaging, and large‑scale systems, and hiring in silicon photonics, co‑packaged optics, and optical AI hardware has accelerated. Investors, in turn, are building thematic exposure across photonic chipmakers, device manufacturers, and equipment vendors as a hedge against bottlenecks in any single layer.

Stories like Dai Jun’s—an engineer‑founder who launched RoboTechnik in 2011 and now controls roughly 17% of a company that has vaulted him into the billionaire ranks—illustrate how this niche corner of the supply chain has become a frontline beneficiary of AI data‑center build‑outs. For global allocators, the message is clear: some of the most leveraged plays on AI scale may sit not in headline GPUs, but in the quiet optics and equipment names that make the bandwidth math work.

From “Solution in Search of a Problem” to Market Narrative

Silicon photonics’ reputation arc now runs in parallel with the fortunes of companies like RoboTechnik. What once looked like an elegant technology hunting for relevance has become an indispensable tool for solving three of the AI data center’s hardest problems: bandwidth, latency, and power.

At the same time, the optics supply chain that enables SiPh is spawning a new class of wealth, listings, and capital flows stretching from Suzhou factories to Hong Kong trading floors. In other words, silicon photonics finally found the problem it solves—and in the process, it also found a story that markets are more than happy to price.

The Sources


[1] Chinese AI Optics Billionaire Eyes Dual Listing In Hong Kong After … https://www.forbes.com/sites/zinnialee/2026/05/15/chinese-ai-optics-billionaire-eyes-dual-listing-in-hong-kong-after-340-stock-rally/
[2] Data Centers Are Already Silicon Photonics’ Killer Application https://www.idtechex.com/en/research-article/data-centers-are-already-silicon-photonics-killer-application/31205
[3] Industry insight: photonics to scale AI data centers | npj Nanophotonics https://www.nature.com/articles/s44310-025-00105-1
[4] A New Era in Data Center Networking with NVIDIA Silicon Photonics … https://developer.nvidia.com/blog/a-new-era-in-data-center-networking-with-nvidia-silicon-photonics-based-network-switching/
[5] History of Silicon Photonics | DustPhotonics https://www.dustphotonics.com/an-overview-of-the-evolution-of-silicon-photonics/
[6] Silicon photonics – Wikipedia https://en.wikipedia.org/wiki/Silicon_photonics
[7] History and Current Status | Passive Silicon Photonic … https://pubs.aip.org/books/monograph/51/chapter/20660965/History-and-Current-Status
[8] Solutions In Search of a Problem | The Networking Nerd https://networkingnerd.net/2021/02/12/solutions-in-search-of-a-problem/
[9] Light into How silicon photonics is powering the AI data center … https://blog.st.com/data-silicon-photonics-ai/
[10] Integrated Photonics for AI Hardware Acceleration: How Light Is … https://www.findlight.net/blog/photonics-ai-acceleration/
[11] How AI Is Transforming Hiring Demand in Silicon Photonics https://www.acceler8talent.com/resources/blog/how-ai-is-transforming-hiring-demand-in-silicon-photonics/
[12] Silicon Photonics In The Data Center: What A CMOS Exec Needs To … https://semiengineering.com/silicon-photonics-in-the-data-center-what-a-cmos-exec-needs-to-know/
[13] AI Optics Boom Propels Founder Of Photonic Chip Maker Into The … https://www.forbes.com/sites/ywang/2026/03/20/ai-optics-boom-propels-founder-of-photonic-chip-maker-into-the-billionaire-ranks/
[14] RoboTechnik Sees 340% Stock Surge Amid AI Optics Boom – LinkedIn https://www.linkedin.com/posts/zinnia-lee-796664185_chinese-ai-optics-billionaire-eyes-dual-listing-activity-7460956795696619520-IRTG
[15] Chinese AI Optics Billionaire Eyes Hong Kong Dual Listing After 340 … https://img2-azcdn.newser.com/aticles-market/Chinese-AI-Optics-Billionaire-Eyes-Hong-Kong-Dual-Listing-After-340-Stock-Surge-12-2591
[16] Forbes https://www.forbes.com/home_asia/feeds/afx/2006/06/05/afx2794908.html
[17] Hong Kong Stocks Log Best Year Since 2017 as AI Boom Fuels … https://www.wsj.com/finance/stocks/hong-kong-stocks-log-best-year-since-2017-as-ai-boom-fuels-tech-rally-d4bfdf87
[18] China’s stock rally on AI optimism to stretch fundraising frenzy in 2026 https://www.scmp.com/business/china-business/article/3339859/chinas-valuation-driven-stock-rally-ai-optimism-stretch-fundraising-frenzy-2026
[19] This AI IPO surged 400% on its Hong Kong stock market debut https://www.tradingview.com/news/invezz:c5d30635a094b:0-this-ai-ipo-surged-400-on-its-hong-kong-stock-market-debut/
[20] Chinese AI Startups Extend Post-Listing Rally in Hong Kong https://www.caixinglobal.com/2026-01-12/chinese-ai-startups-extend-post-listing-rally-in-hong-kong-102403004.html
[21] #ai #technews #investing #stockmarket #billionaire | Rick Spair https://www.linkedin.com/posts/rickspair_ai-technews-investing-activity-7460957984559427584-N00D
[22] [5/15 08:00] US-China AI Safety Talks / Chinese AI Optics … – YouTube https://www.youtube.com/watch?v=-kMejZuCxPM
[23] Chinese AI Optics Billionaire Eyes Hong Kong Dual Listing After 340 … https://img1-cdn.newser.com/first-dry/Chinese-AI-Optics-Billionaire-Eyes-Hong-Kong-Dual-Listing-After-340-Stock-Surge-12-2591
[24] 3 Chinese AI, robotics stocks gain in Hong Kong debuts https://www.scmp.com/business/banking-finance/article/3339109/three-chinese-tech-stocks-gain-hong-kong-debuts-investors-jump-ai-robotics
[25] Top China Tech Names for U.S. Investors Amid Massive Rally https://pro.thestreet.com/trade-ideas/top-china-tech-names-for-u-s-investors-amid-massive-rally
[26] Forbes – Liu Debing, chairman and cofounder of Chinese AI model … https://www.facebook.com/forbes/photos/liu-debing-chairman-and-cofounder-of-chinese-ai-model-company-knowledge-atlas-te/1254616839861637/

May 22, 2026

The Insulin Pump That Could Spark a Bidding War: Modular Medical’s Pivot Targets Millions Still on Manual Injections -( $ABT $JNJ $MDT $MMED $MODD $PODD $TNDM )

Modular Medical (MODD) has cleared a crucial regulatory hurdle that positions its Pivot insulin patch pump as a potential game-changer in the $7 billion diabetes technology market, with FDA 510(k) clearance paving the way for commercial shipments by the end of Q2 2026. CEO Jeb Besser’s confident proclamation—that Pivot’s tubeless design addresses “complexity, bulkiness, and high cost”—signals the company’s ambition to convert millions of insulin-dependent patients still tethered to manual injections into pump therapy adopters. The device enters a rapidly expanding tubeless insulin pump market projected to surge from $2.86 billion in 2026 to $16.69 billion by 2035, driven by a 21.4% compound annual growth rate.

From Clearance to Commerce

The FDA milestone represents years of focused innovation culminating in a device designed for the “almost-pumpers”—patients who’ve been reluctant to adopt traditional pump therapy due to its intimidating learning curve and physical bulk. Pivot’s removable, tubeless architecture with smartphone connectivity offers a streamlined entry point that could unlock a massive untapped patient population currently managing diabetes through multiple daily injections. With manufacturing validation lots already in production and a software roadmap advancing toward automated insulin delivery features, Modular Medical has positioned itself to de-risk its commercial launch while keeping pace with industry leaders developing closed-loop systems.

The company’s near-term agenda extends beyond U.S. market penetration, with European CE Mark progress targeted for the second half of 2026—a strategic move that would open access to additional high-value markets. Besser’s emphasis on “rapid commercialization strategy” and “additional software enhancements” suggests the company understands that in diabetes technology, standing still means falling behind competitors like Insulet (PODD), Medtronic (MDT), and Tandem (TNDM) who are aggressively advancing their automated insulin delivery platforms.

The Acquisition Calculus

Modular Medical’s fresh FDA clearance arrives at a moment when consolidation pressures are reshaping the diabetes technology landscape, seemingly making MODD an attractive acquisition target for established players seeking to fortify their product portfolios. Insulet Corporation (PODD), which dominates the patch pump segment with its Omnipod franchise, could view Pivot as either a competitive threat worth neutralizing or a complementary technology that broadens its addressable market among price-sensitive patients. The precedent is clear: Tandem Diabetes Care (TNDM) approximately $210 million potential total consideration for Switzerland’s AMF Medical in 2023 specifically to acquire patch pump technology that was not and still is not FDA cleared with the idea to challenge Insulet’s market position, demonstrating that major players will write substantial checks to stay competitive.

Medtronic (MDT) also announced a $738 million deal to acquire the South Korean wearable insulin patch maker called EOFlow in May 2023, but also officially terminated the acquisition in December 2023 citing “multiple breaches” under the acquisition agreement. The termination came shortly after rival diabetes company Insulet sued EOFlow for patent infringement, which resulted in a preliminary injunction against EOFlow’s devices. On March 26, 2026 Medtronic’s rolled out its diabetes business, MiniMed Group, through an initial public offering (IPO), on the Nasdaq under the ticker symbol “MMED”. The company sold 28 million shares at $20.00 each to raise $560 million, valuing the diabetes-tech firm at $5.6 billion. Medtronic retains roughly 90%. Medtronic’s MiniMed with a significant amount of cash and a believed need to add to their diabetes line up, could possibly view Modular Medical as a shortcut to accelerate its tubeless strategy while adding an FDA-cleared platform ready for immediate commercialization.

Abbott Laboratories (ABT) also presents an intriguing fit given its glucose sensing dominance and recent $21 billion acquisition of Exact Sciences in early 2026, signaling an appetite for transformative diabetes and diagnostics deals. Abbott has emerged as the most sought-after partner in diabetes technology due to its continuous glucose monitoring prowess, and pairing that sensor expertise with Pivot’s accessible pump design could create a vertically integrated closed-loop system targeting the enormous type 2 diabetes market.

Even Johnson & Johnson (JNJ), historically active in diabetes care and listed among key tubeless pump market players, could rationalize an acquisition to re-enter insulin delivery after previously exiting the space. The strategic logic for any acquirer hinges on three factors: Pivot’s differentiated simplicity addressing conversion barriers, its FDA clearance de-risking commercial timelines, and the explosive growth trajectory of a tubeless pump market expanding at over 20% annually. For companies with established distribution channels, sales forces calling on endocrinologists, and existing diabetes patient relationships, bolting on Modular Medical’s technology could accelerate market share capture faster than internal development—particularly as the window to compete with Insulet’s early-mover advantage continues to narrow.

The Sources


[1] Modular Medical wins FDA nod for tubeless insulin patch pump https://www.drugdeliverybusiness.com/modular-medical-fda-clearance-pivot-pump/
[2] Let’s call this good news Friday, with a new insulin pump … – Instagram https://www.instagram.com/p/DXPxTjhEjoz/
[3] Modular Medical Achieves Key Manufacturing Milestone for Pivot … https://www.biospace.com/press-releases/modular-medical-achieves-key-manufacturing-milestone-for-pivot-tubeless-insulin-patch-pump
[4] Tubeless Insulin Pump Market Size, Share & Industry Forecast 2035 https://www.researchnester.com/reports/tubeless-insulin-pump-market/6368
[5] Modular Medical Receives FDA Clearance for Pivot Insulin Patch … https://www.linkedin.com/posts/sejal-rathod18_modular-medical-wins-fda-nod-for-tubeless-activity-7448078890520223744-VJ2f
[6] Insulet sizes up competition as Tandem, Medtronic plan new insulin … https://www.medtechdive.com/news/insulet-patch-pump-competition-tandem-medtronic/708845/
[7] As Competitive Landscape Shifts Diabetes Companies Jockey for … https://www.mystrategist.com/medtech-strategist/article/as_competitive_landscape_shifts_diabetes_companies_jockey_for_position-2.html
[8] Medtech M&A starts off strong in 2026 https://www.medtechdive.com/news/medtech-ma-starts-off-strong-in-2026/813228/
[9] Tandem offers $216M for insulin patch pump maker AMF Medical https://www.fiercebiotech.com/medtech/tandem-inks-216m-deal-amf-medical-and-its-rechargeable-insulin-patch-pump
[10] Tandem agrees to buy AMF, challenging Insulet for insulin pump … https://www.linkedin.com/posts/jbollenbacher_tandem-agrees-to-buy-amf-challenging-insulet-activity-7009216171694571520-kpWD
[11] Abbott Reports First-Quarter 2026 Results; Updates Guidance to … https://www.prnewswire.com/news-releases/abbott-reports-first-quarter-2026-results-updates-guidance-to-reflect-acquisition-of-exact-sciences-302744652.html
[12] Abbott Is Becoming the Most Sought-After Partner in Diabetes Tech https://www.mddionline.com/diabetes/abbott-is-becoming-the-most-sought-after-partner-in-diabetes-tech
[13] Tubeless Insulin Pump Market Overview, Size, Share, Analysis https://www.precisionbusinessinsights.com/market-reports/tubeless-insulin-pump-market
[14] Tubeless Insulin Pump Market Size & Growth Analysis by 2030 https://www.alliedmarketresearch.com/tubeless-insulin-pump-market-A12064
[15] Insulin Patch Pumps Market Size, Share Report 2026 https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report

May 22, 2026

Qubits, Chips and Rare Earths: Inside America’s New National Portfolio Strategy -( $IBM $IONQ $GFS $MP $RGTI $QBTS $QUBT )

The United States’ latest move into quantum computing reads less like a science project and more like a sprawling, government-run portfolio spanning semiconductors, steel, nuclear power and rare earth metals—just with a few more qubits than usual.

Quantum Becomes the New National Industry

In Washington’s newest industrial experiment, the Trump administration is reportedly extending its investment spree from chips and rare earths into quantum computing, offering roughly 2 billion dollars in grants to nine companies in exchange for equity stakes. The idea is that if taxpayers are footing the bill for cutting‑edge hardware, they should also enjoy a sliver of any upside that comes when those qubits finally earn their keep.

The centerpiece is a proposed 1 billion dollar award to International Business Machines Corp. (IBM), which will build what officials pitch as America’s first purpose‑built “quantum foundry”—a kind of fabrication facility where quantum machines and components can graduate from lab curiosity to reliable infrastructure. It is the kind of project that lets policymakers talk about “strategic capacity” and “resilience” while quietly inching Uncle Sam closer to becoming a long‑term tech investor.

A Portfolio That Thinks Like a Hedge Fund

Quantum may be the shiny new object, but it’s being dropped into a portfolio that already ranges from semiconductors to steel, nuclear reactors and rare earth supply chains. The through‑line is geopolitical: in each case, Washington is deciding that certain technologies and materials are too important to leave entirely to the invisible hand and quarterly guidance.

Semiconductors are the familiar anchor, with GlobalFoundries Inc. (GFS) in line for about 375 million dollars and the government taking an equity interest estimated around 1 percent—small enough to keep markets calm, large enough to show this is more than a grant with patriotic branding. On the materials side, the government has already taken stakes in rare‑earth players such as MP Materials Corp. (MP), which operates one of the few non‑Chinese rare‑earth mines, and a magnet‑maker known as Vulcan Elements, aiming to shore up the permanent magnets that make everything from electric vehicles to missiles spin.

The result looks suspiciously like a diversified national balance sheet: qubits via IBM (IBM), fabrication capacity via GlobalFoundries (GFS), magnets and rare earths via MP Materials (MP) and Vulcan Elements, plus earlier bets in nuclear fuel and heavy industry. If the 20th century’s big question was which companies filled the Dow, the 21st century’s version might be which ones end up on the Department of Commerce’s cap table.

Quantum Start‑Ups Join the Club

While IBM (IBM) and GlobalFoundries (GFS) give the program blue‑chip gloss, the more speculative action is happening in the pure‑play quantum names that now find themselves negotiating term sheets with Washington. D‑Wave Quantum Inc. (QBTS), the annealing‑focused pioneer that has been selling early quantum systems for years, is in line for around 100 million dollars; Rigetti Computing Inc. (RGTI), which builds superconducting‑qubit machines, is in the same ballpark.

A cluster of other firms—often still closer to the lab bench than the earnings call—rounds out the list. Atom Computing, PsiQuantum, Infleqtion and Quantinuum are widely cited as participants or likely beneficiaries, though several remain privately held and therefore more familiar to venture capitalists than to retail investors. For the public‑market crowd, names like IonQ Inc. (IONQ) and Quantum Computing Inc. (QUBT) sit just offstage, as investors parse whether government equity programs eventually sweep them in as well.

Collectively, these deals illustrate how the state is trying to smooth out the notorious boom‑bust cycle of frontier hardware. In exchange, the firms accept that their next big investor is less a Sand Hill Road partnership and more a cabinet department with a fondness for compliance paperwork.

How the Equity Experiment Works

The mechanics of these arrangements are straightforward in outline and complex in execution: companies receive grants under the CHIPS Act and related programs, while the government receives a minority, non‑controlling equity stake. For IBM (IBM), that billion‑dollar check comes paired with a slice of stock that turns the federal government into a small but real shareholder; for GlobalFoundries (GFS), officials expect a similar arrangement at a lower dollar level and roughly 1 percent ownership.

Smaller quantum firms such as D‑Wave Quantum (QBTS) and Rigetti Computing (RGTI) are reportedly in talks for at least 10 million dollars each, enough to fund additional hardware generations without relying solely on the next capital raise. Officials argue that this structure gives taxpayers a shot at capturing upside if quantum turns into a commercially meaningful industry, rather than leaving all future gains to private shareholders.

The move also sets a precedent: if quantum grants come with equity hooks, it’s easier to imagine future rounds in areas such as advanced nuclear, grid‑scale storage or new rare‑earth refining capacity operating on similar terms. At that point, the question for CFOs may be less whether to take government money and more which alphabet soup of programs offers the most favorable cap‑table math.

A Strategic Bet on Qubits and Supply Chains

The strategic logic behind this portfolio is that quantum machines, like chips and rare earths, are both economic assets and geopolitical tools. A mature quantum sector promises speed‑ups in areas such as optimization, cryptography and materials science, even if the revenue line is still more theory than practice.

By backing players from IBM (IBM) and GlobalFoundries (GFS) to MP Materials (MP) and Vulcan Elements, Washington is trying to stitch together an ecosystem that can fabricate, power and supply the hardware stack without leaning on rival powers. Think of it as a supply chain that runs from the rare‑earth mine to the superconducting chip, with the federal government acting as both limited partner and ultimate customer.

Critics worry about politicizing capital allocation, but the administration’s view is that the larger risk lies in leaving critical technologies under‑invested or over‑concentrated abroad. If the price of more resilient supply chains is that Washington occasionally sounds like a sector‑focused hedge fund, officials appear willing to live with the comparison.

Market Reaction: Qubits Meet Quotes

Investors, for their part, have treated the news as a fresh catalyst in a sector prone to long droughts between headlines. IBM (IBM) shares reportedly jumped more than 7 percent after the quantum foundry plan surfaced, while some of the smaller quantum names saw moves of up to 20 percent as traders extrapolated what a government on their shareholder registry might mean.

GlobalFoundries (GFS), already a key beneficiary of earlier chip subsidies, stands to deepen its relationship with Washington, giving investors another reason to treat the stock as a long‑cycle beneficiary of industrial policy. And even downstream players such as MP Materials (MP) have been pulled into the narrative, as markets revisit which companies sit closest to the converging fault lines of technology, security and policy.

Of course, quantum’s revenue line still looks more like a thesis than a cash flow statement, and the path from prototype system to profitable product remains hazy. But in a market where imagination often trades at a premium, the promise of billion‑dollar foundries and government‑backed balance sheets is enough to put qubits squarely back on investors’ dashboards.

Learn More By Watching This Video

This video examines the transformation of the global critical minerals supply chain at a time when resilience, innovation, and policy leadership are more urgent than ever. From mineral extraction and refinement, to government action and private sector innovation, each episode will bring you closer to the people and ideas shaping the future of resource security.

The Sources


[1] US move into quantum computing adds to a portfolio that spans … https://finance.yahoo.com/economy/policy/article/us-move-into-quantum-computing-adds-to-a-portfolio-that-spans-semiconductors-steel-nuclear-and-rare-earths-173919828.html
[2] $100M Diraq: $38M Also in: Atom Computing, PsiQuantum … https://x.com/insidermonkey/status/2057434954846400612
[3] Trump administration in talks to take stakes in quantum-computing … https://www.reuters.com/business/trump-administration-talks-take-stakes-quantum-computing-firms-wsj-reports-2025-10-23/
[4] IBM and U.S. Department of Commerce Announce America’s First … https://newsroom.ibm.com/ibm-and-u-s-department-of-commerce-announce-americas-first-purpose-built-quantum-foundry
[5] US move into quantum computing adds to a portfolio that spans … https://www.aol.com/articles/us-move-quantum-computing-adds-173919000.html
[6] First rare earths and chips, now quantum computers – Reddit https://www.reddit.com/r/StockMarket/comments/1odzvam/first_rare_earths_and_chips_now_quantum_computers/
[7] VanEck Rare Earth and Strategic Metals ETF (US) – REMX https://www.vaneck.com/us/en/investments/rare-earth-strategic-metals-etf-remx/
[8] Quantum computing stocks spike on reported US interest in stakes … https://www.investing.com/news/stock-market-news/us-govt-in-talks-to-take-stakes-in-quantumcomputing-firms-wsj-reports-4303307
[9] 8 Best Quantum Computing Stocks to Buy in 2026 – U.S. News Money https://money.usnews.com/investing/articles/best-quantum-computing-stocks-to-buy
[10] Finance and Markets https://www.wsj.com/finance
[11] Trump Administration in Talks to Take Equity Stakes in Quantum … https://www.wsj.com/business/entrepreneurship/trump-administration-in-talks-to-take-equity-stakes-in-quantum-computing-firms-60ee5143
[12] Best Quantum Computing Stocks to Buy for May 2026 https://www.zacks.com/featured-articles/361/best-quantum-computing-stocks
[13] Dow Jones – Trusted News & Data https://www.dowjones.com
[14] Quantum Computing & Nuclear Energy – YouTube https://www.youtube.com/watch?v=5iFwzUomXns
[15] 3 Stocks & 1 ETF To Buy Now For Quantum Computer Investing? https://www.youtube.com/watch?v=vVVyzya6gr4

May 21, 2026

When AI Ate Capex: Why Trillion‑Dollar Tech Spend May Still Be Too Small -( $GS $NOK $NVDA )

Global AI spending is barreling toward the trillion‑dollar mark faster than Wall Street’s models can refresh, and the odds are high that current estimates still understate the size of the build‑out. Nokia’s (NOK) new AI Networking Innovation Lab is one of the more tangible signs that the race is shifting from abstract “AI hype” to hard infrastructure—chips, power, and networking muscle built to keep the party going.

Trillion‑Dollar AI: Why the Bar Is Too Low

Banks now peg AI capital expenditure for the largest tech platforms at roughly 700 billion dollars this year—double last year’s pace—with a glide path to north of 1 trillion dollars in annual spending as soon as next year. That’s not lifetime spend; that’s the yearly run‑rate just to feed the current generation of models and data centers.

Zoom out, and scenario work from Goldman Sachs (GS) suggests global AI infrastructure—compute, data centers, and power—could soak up about 7.6 trillion dollars between 2026 and 2031. Their baseline implies AI capex climbing from roughly 765 billion dollars in 2026 to around 1.6 trillion dollars a year by 2031, even before you account for the inevitable tendency of cheaper compute to create new use cases and fresh demand.

The Physical Internet Behind “Magic” AI

Behind each breezy AI query sits a very un‑breezy industrial stack: accelerators, cabling, liquid cooling, and power draws that rival midsize countries. System designers are now talking about data centers in terms of power density per rack, megawatts per site, and the economics of custom power generation, not just “cloud regions” and availability zones.

Costs are rising accordingly. Traditional hyperscale data centers could be built at roughly 10 million dollars per megawatt; next‑gen AI facilities are increasingly modeled at 15–20 million per megawatt as cooling, redundancy, and integration get more complex. That means even small tweaks in design assumptions—cooling method, redundancy level, rack density—can move cumulative capex by hundreds of billions of dollars.

Silicon Shelf Life: The Most Expensive Expiration Date in Tech

The single biggest swing factor in total AI spend is the useful life of AI silicon—the GPUs and accelerators doing the heavy lifting. Shorten that practical life from, say, five years to three as new architectures arrive with step‑function performance jumps, and you compress replacement cycles enough to add hundreds of billions to the tab over a decade.

Goldman’s sensitivity work highlights how a 50,000‑dollar accelerator depreciated over five years looks reasonable on paper, but if it becomes uneconomic to run sooner because a new generation doubles performance per dollar, the operator is still stuck carrying an asset that no longer earns its keep. Multiply that by hundreds of thousands of devices and you don’t just move earnings—you reshape the economics of the entire ecosystem.

Chips, Margins, and the Elasticity Question

Today’s AI build‑out is dominated by general‑purpose accelerators, with NVIDIA Corporation (NVDA) still the reference point for data center GPUs and system design. But a growing share of workloads will inevitably migrate to more specialized silicon—application‑specific integrated circuits tailored for particular models or tasks—as buyers look to claw back some of the 70‑plus percent gross margins embedded in merchant GPUs.

Whether that lowers total AI capex or simply gives the world bigger models for the same money comes down to demand elasticity. In an elastic world—and most AI bulls live firmly in this camp—cheaper compute doesn’t reduce spending; it encourages more training runs, larger context windows, and more aggressive deployment, keeping the aggregate investment envelope roughly the same while shifting who captures the margin.

Bottlenecks: Stretching the Timeline, Not Shrinking the Bill

There are plenty of bottlenecks that threaten to slow—not stop—the trillion‑dollar build‑out: interconnection queues for power, long lead times for transformers, shortages of specialized labor, and permitting timelines that move at something less than machine speed. These frictions “elongate” the build‑out, widening the gap between when capital is committed and when new compute capacity actually comes online.

In the base case, these delays don’t meaningfully change the total capital required; they mostly reshuffle timing and introduce more volatility into returns. The real risk is psychological: if enough projects stall at once, the narrative can flip from “inevitable AI future” to “will the demand really be there?”, and that’s when boardrooms start sharpening pencils on the next capex cycle.

Nokia’s AI Networking Lab: Wiring the Trillion‑Dollar Future

Into this backdrop steps Nokia Corporation (NOK), with the launch of its AI Networking Innovation Lab in Sunnyvale, California—a brick‑and‑mortar bet that tomorrow’s AI edge will partly be won in the network. The lab is designed as a testbed for high‑performance data center networking tailored to large‑scale AI training and real‑time inference, effectively giving carriers, cloud providers, and enterprises a sandbox where they can break things with intent before deploying at scale.[3]

Nokia plans to use the facility to design, test, and validate new data center networking architectures, integrating advanced switching silicon, AI‑optimized protocols, and new hardware platforms for AI‑centric environments. It also serves as a showcase for “Nokia Validated Designs”—reference configurations that aim to de‑risk network build‑outs and shorten time‑to‑deployment for partners who cannot afford to discover network bottlenecks after they’ve already spent billions on compute.

Ecosystem Partners: A Who’s Who of AI Plumbing

The lab will collaborate with a roster of AI and cloud partners, including server makers and storage innovators that are central to large‑scale training clusters and inference fabrics. The goal is not just speeds‑and‑feeds benchmarking, but co‑development of practical deployment blueprints that customers can lift directly into production.

In practice, that means validating real‑world scenarios—multi‑tenant training farms, low‑latency inference at scale, and architectures where networking, compute, and storage operate as a tightly coupled system rather than as loosely connected boxes. For investors, this kind of lab work is less about press‑release optics and more about defending share in a world where AI data centers are rapidly becoming the new “national infrastructure” for the digital economy.

Why Networking Is the Quiet Winner of AI Capex

From an investor’s lens, AI networking has all the makings of a secular tailwind: rising bandwidth per node, more east‑west traffic inside data centers, and demanding synchronization requirements for training large models. As accelerators become faster and more power‑hungry, the cost of under‑provisioned networks rises—it makes little sense to feed cutting‑edge GPUs through a straw.

Nokia’s move positions it squarely in the path of that capex, competing alongside and often partnering with switch and routing vendors whose fortunes are increasingly tied to AI clusters rather than traditional enterprise workloads. In a world where 7–8 trillion dollars of AI infrastructure is on the table over the next half‑decade, being at the networking layer is a comfortable place to sit—somewhat insulated from headline model risk, yet indispensable to every serious deployment.

Markets, Multiples, and the New “Capex Cycle”

For equity markets, the trillion‑dollar AI spend is doing double duty: it is both a growth narrative and a macro stabilizer. Business investment in AI has become a more important driver of economic growth than consumer spending in many models, with the largest AI investors now making up nearly half of equity market capitalization. That concentration means AI capex cuts would feel a lot like a synchronized tightening cycle across some of the most systemically important companies in the index.

At the same time, banks and institutional allocators are increasingly forced to treat AI infrastructure as its own asset‑class‑in‑waiting—something closer to long‑duration utilities plus semis plus software, all blended into one capex‑heavy, depreciation‑rich line item. The market’s core question is shifting from “Is this a bubble?” to “Are our spreadsheets even using the right assumptions on chip life, data center costs, and power?”—an unusually philosophical turn for an industry that usually prefers its debates settled in basis points.

The Punchline for Investors

Across scenarios, the consistent theme is that current 1‑trillion‑dollar AI spend projections are less a ceiling and more a staging area. With baseline models already pointing to 7.6 trillion dollars of AI infrastructure capex from 2026 to 2031 and realistic upside if silicon turns over faster or data center costs drift higher, the question for investors is not whether the number is big; it is whether their portfolios are positioned where the spend actually lands.

In that context, Nokia’s AI Networking Innovation Lab is a useful tell: the industry is quietly acknowledging that networking is no longer a supporting character in the AI story—it is part of the main cast. And if history is any guide, when the plumbing becomes strategic, the companies that design the pipes tend to do just fine over a cycle or two.

The Sources


[1] The Assumptions Shaping the Scale of the AI Build-Out https://www.goldmansachs.com/insights/articles/tracking-trillions-the-assumptions-shaping-scale-of-the-ai-build-out
[2] AI’s $1 trillion risk keeps growing – Axios https://www.axios.com/2026/05/05/ai-spending-stocks-economy
[3] Nokia launches AI networking lab to drive co-innovation with … https://finance.yahoo.com/sectors/technology/articles/nokia-launches-ai-networking-lab-070000573.html
[4] Big Tech’s AI rollout could drive $1.1 trillion in spending next year … https://www.facebook.com/Reuters/posts/big-techs-ai-rollout-could-drive-11-trillion-in-spending-next-year-fueling-globa/1538451118145615/
[5] AI spending to top $2 trillion next year – Gartner – Telecoms https://www.telecoms.com/ai/ai-spending-to-top-2-trillion-next-year-gartner
[6] Big 4 has spent almost a TRILLION on AI : r/stocks – Reddit https://www.reddit.com/r/stocks/comments/1mehwlc/big_4_has_spent_almost_a_trillion_on_ai/
[7] A Special Benefit for https://americas.hsmai.org/wp-content/uploads/sites/16/2020/05/CHDM-2019-Book-for-Scholarships-hr.pdf
[8] AI Spending To Hit $1.5 Trillion In 2025 And $2 Trillion In 2026 https://www.youtube.com/watch?v=4RdBZKWLatY
[9] Nokia’s AI strategy gathers momentum with new lab – Telecoms https://www.telecoms.com/digital-ecosystem/nokia-s-ai-strategy-gathers-momentum-with-new-lab
[10] Writing and Editing For Digital Media (PDFDrive) PDF – Scribd https://www.scribd.com/document/479437428/Writing-and-Editing-for-Digital-Media-PDFDrive-pdf
[11] AI Cap Ex Spend of $1 Trillion for 2027 – AI Bubble is a Hallucination https://www.youtube.com/watch?v=523lgM5oefE
[12] Nokia unveils plans to build innovation lab in Dubai, UAE – SDxCentral https://www.sdxcentral.com/news/nokia-unveils-plans-to-build-innovation-lab-in-dubai-uae/
[13] Three Rivers Databases: By Subject – CT State Libraries https://library.ctstate.edu/threerivers/databases
[14] The $2.8 Trillion Question: Can Big Tech’s AI Spending Earn Its Keep? https://www.linkedin.com/pulse/28-trillion-question-can-big-techs-ai-spending-earn-its-puneet-gupta-dlnnc
[15] Nokia Bell Labs Demonstrates AI Benefits for Future Networks https://www.youtube.com/watch?v=pgc4RqXdqUI

May 21, 2026

May 21, 2026 – AI, Banks and Small Caps Walk Into a Rally: Wall Street Loves the Punchline -( $ALAB $AMWL $BZFD $EPRX $FMC $GOVX $MCD $MODD $NOK $PPTA $SER $SOAR $RGTI $TSLA Rise!)

U.S. stocks extended their rebound on Thursday, May 21, 2026, with investors leaning back into risk as hopes for a U.S.–Iran agreement tempered recent geopolitical anxiety and markets digested a dense slate of Fed commentary and macro data. Gains were broad-based across major indices, while renewed focus on critical minerals policy put names like Perpetua Resources (PPTA, $31.55, +18.08% in the aftermarket) in the spotlight after it secured multibillion‑dollar government-backed financing for its Idaho gold–antimony project.

Equity markets today

Wall Street built on Wednesday’s strength, with all three major U.S. benchmarks finishing higher as the bid for risk assets persisted. The Dow Jones Industrial Average climbed about .55% to close just above the 50,285 mark, led by financials, with Goldman Sachs rising .62% as investors rotated toward rate‑sensitive and capital‑markets names. The S&P 500 advanced around .17%, while the tech‑heavy Nasdaq Composite gained about .09%, continuing a pattern of mega‑cap and growth leadership that has characterized much of the 2026 rally. Small caps, as proxied by the Russell 2000, outperformed with gains north of .93%, signaling improving risk appetite beneath the mega‑cap surface.

At the sector level, technology and communication services remained key engines of performance, supported by ongoing enthusiasm around artificial intelligence and cloud infrastructure, while cyclicals such as industrials and financials caught a bid on the back of better‑than‑feared macro prints and easing geopolitical risk premia. Energy shares lagged as crude oil ($97.62, -.65%) stayed volatile amid shifting expectations around a potential U.S.–Iran deal and its implications for future oil supply. For context, April’s outsized rally pushed the Nasdaq up more than 15% and the S&P 500 over 10% year‑to‑date, leaving positioning extended but momentum still intact into late May.

Macro and policy backdrop

The macro narrative today remained anchored on three pillars: Fed policy, inflation persistence, and geopolitics. Investors continued to parse recent Federal Reserve communications that acknowledged sticky inflation but also signaled patience, reinforcing expectations that the Fed will prioritize a longer hold at current rates rather than a hawkish surprise hike. Market participants are increasingly focused on the balance between resilient growth and slowly moderating price pressures, as global forecasters now project 2026 world GDP growth in the low‑3% range with modest upside to prior estimates.

Geopolitically, markets took comfort from fresh signs that a U.S.–Iran accord may be edging closer, after weeks in which stalled talks and sporadic escalations had driven bouts of risk‑off behavior and oil price spikes. That incremental relief helped compress energy‑related risk premia and supported rate‑sensitive assets by tempering fears of a renewed inflation shock from commodities. Still, Fed minutes released this week underscored that policymakers remain uneasy about the pace of disinflation, a theme likely to keep rate‑cut expectations subdued and preserve a “higher for longer” rate regime into 2027.

Notable corporate and sector stories

One of the day’s most notable headlines came from the critical‑minerals space, where Perpetua Resources advanced toward securing roughly 2.7–2.9 billion dollars in U.S. government‑backed loan support for its Stibnite gold–antimony project in Idaho. The Export‑Import Bank has notified Congress of a proposed package that would fund the bulk of the project’s upfront capital costs, reflecting Washington’s strategic push to diversify supply chains away from China for key defense‑related metals such as antimony. The Stibnite project has long been framed as both a domestic supply security play and an environmental flashpoint, drawing legal challenges from local stakeholders even as federal agencies move the financing process forward.

From a market-structure perspective, the Perpetua story underscores how industrial policy and national security considerations are increasingly intersecting with mining and materials valuations. Investors in the metals and mining complex are now forced to underwrite not only commodity‑price risk, but also regulatory timelines, environmental negotiations, and the durability of bipartisan support for strategic‑materials initiatives. In practice, that can translate into more binary outcomes for single‑asset developers, but it also creates a policy‑supported floor for projects deemed systemically important to U.S.

Positioning and narrative for investors

For equity investors, today’s tape fits neatly into the ongoing narrative of “climbing the wall of worry” in a high‑rate, high‑earnings environment. Stronger‑than‑expected corporate results, especially in technology and select financials, continue to offset concerns about policy rates and geopolitical tail risks, keeping the S&P 500 and Nasdaq on record‑setting trajectories despite frequent tactical pullbacks. The resurgence in small caps and cyclicals hints that the rally is broadening beyond the AI‑heavy mega‑cap cohort, an important marker of durability if it persists into early summer.

In the macro backdrop, global outlook revisions show modest upgrades to growth projections, particularly in developed markets, while central banks outside the U.S. contemplate further tightening to tame residual inflation. For asset allocators, that mix argues for maintaining a pro‑equity stance but with a more selective tilt: overweight high‑quality growth and AI beneficiaries, balance them with cyclicals levered to real‑economy expansion, and maintain risk controls around energy and geopolitical sensitive exposures.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Rigetti Computing, Inc. (RGTI, $22.04, +30.57%)

Rigetti Computing, Inc., a pioneer in full-stack quantum-classical computing, announced (May 21) that it has signed a letter of intent (“LOI”) with the U.S. Department of Commerce (the “Department”) for an award of up to $100 million in funding over three years to accelerate superconducting quantum computing R&D.

Astera Labs, Inc. (ALAB, $297.84, +3.60%)

Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced preliminary financial results for the first quarter of fiscal year of 2026, ended March 31, 2026.

Amwell® (AMWL, $7.93, +.51%)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-
enabled healthcare platform, highlighted (May 18) results from an independently led, National Institute of Mental Health-funded randomized trial published in Nature Human Behaviour examining SilverCloud® by Amwell®, the company’s digital behavioral health solution.

Amwell announced (May 5) financial results for the first quarter ended Mar. 31, 2026.
“Entering 2026, Amwell’s main focus was to consolidate our platform to fulfill the unmet needs of our Payer and Provider customers. The Technology-Enabled Care infrastructure we have developed to fill that gap in the market continues to gain traction as customers recognize its clear advantages: lower costs, better outcomes, stronger market share and an increased level of control and agility. Our platform is performing well and built to leverage the latest AI-powered innovations, positioning it as essential infrastructure for tech-enabled care delivery,” said Dr. Ido Schoenberg, Chairman and CEO of Amwell. “We are seeing powerful validation of the platform with significant pipeline growth and a number of meaningful renewals. With this momentum and the favorable regulatory tailwinds, Amwell is well-positioned for continued strong execution this year and to reach our goal of positive cash flow from operations in the fourth quarter.”

Eupraxia Pharmaceuticals (EPRX, $6.94, +8.95%)

Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Eurpraxia announced on Friday, May 1, the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas’ Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.

Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.

Modular Medical (MODD, $4.15, +7.79%)

  • Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, saw (May 1) CEO Jeb Besser join Tribe Public’s members to unpack a simple question with big implications: what happens when an “almost‑pumper” market finally meets an FDA‑cleared device built for the rest of us, not just the superusers? Tribe Public hosted its CEO Presentation and Q&A Webinar, “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” on Friday, May 1, 2026, at 8:00 a.m. PT / 11:00 a.m. ET. In keeping with Tribe’s reputation for efficient programming, the session ran approximately 30 minutes, pairing a focused prepared talk with a 5–10 minute live Q&A segment that allowed investors to drill into timelines, capital needs, and commercial strategy. Besser’s formal remarks were framed under the title “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” setting the tone for a discussion that sat at the intersection of regulation, innovation, and recurring‑revenue hardware. By registering, attendees also joined Tribe Public’s membership base, ensuring they will receive future invitations to CEO briefings, sector spotlights, and investor wish‑list events.
  • Modular Medical announced (APRIL 19) the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
  • Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now (April 9) secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.

The InterGroup Corporation (INTG, $37.47)

  • The InterGroup Corporation (NASDAQ: INTG) announced financial (May 11) results for the fiscal third quarter ended March 31, 2026. InterGroup is a diversified holding company with interests in hospitality (through its majority‑owned subsidiary Portsmouth Square, Inc.), real estate operations, and investment transactions. The discussion below is derived from the Company’s Quarterly Report on Form 10‑Q for the quarter ended March 31, 2026. Third Quarter Fiscal 2026 Highlights (Three Months Ended March 31, 2026 vs. 2025) are as follows:
    • Total revenues increased to $20.372 million from $16.824 million (+21%).
    • Income from operations increased to $4.260 million from $2.350 million (+81%).
    • GAAP net income was $0.595 million, compared to a GAAP net loss of $0.750 million in the prior‑year quarter.
    • Net income attributable to InterGroup was $0.457 million, or $0.21 per diluted share, compared to a net loss attributable to InterGroup of $0.578 million, or $0.27 per share, in the prior‑year quarter.
    • Hotel revenues increased to $16.497 million from $12.210 million (+35%). For additional context, Hotel revenues for the quarter ended March 31, 2026 exceeded the comparable pre‑pandemic quarter ended March 31, 2019 by approximately $1.028 million.
    • Real estate revenues were $3.875 million compared to $4.614 million in the prior‑year quarter (‑16%).
    • Net loss from investment transactions was $(0.342) million compared to $(1.379) million in the prior‑year quarter.

Volato Group, Inc. (SOAR, +8.34%) & M2i Global, Inc. (MTWO)

Nokia (NOK, $14.18, +4.11%)

  • Nokia has quietly stitched together a new chapter in its comeback story—one that runs from American living rooms to Pentagon test ranges, and now straight through NVIDIA’s (NVDA) data centers. With NVIDIA’s billion‑dollar vote of confidence in the fall and another blockbuster NVIDIA earnings report due today, the old handset icon is suddenly speaking fluent AI.
  • Nokia announced (May 21) the launch of its AI Networking Innovation Lab, a new center designed to drive co-innovation with AI and cloud partners and accelerate the development of next-generation networking technologies for artificial intelligence (AI) infrastructure. Located within Nokia’s Sunnyvale, California facility, the lab serves as an innovation hub where Nokia will work across advanced AI networking technologies, architectures and ecosystems with a variety of partners to help shape the future of data center networking. AI workloads are fundamentally changing how data center networks must operate. The performance, scale, and precision required to support large-scale AI training and distributed, real-time inference place unprecedented demands on networking infrastructure. To address these challenges, Nokia is adopting a new approach to how technologies are integrated, tested, and deployed from the ground up for the AI era.

NVIDIA (NVDA, $219.51)

Nvidia’s First Quarter Fiscal 2027 earnings report crossed the tape Wednesday, May 20, and the immediate takeaway is that the AI engine is still running at full throttle, even if Wall Street was already leaning hard on the accelerator. The story today is less about whether Nvidia is growing and more about just how far into “infrastructure of AI” territory it has now ventured.

McDonald’s (MCD, $284.12, +1.37%)

  • Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock. The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .

Tesla (TSLA, $417.85, +.14%)

Tesla’s Q1 2026 performance underscored strong revenue growth and signs of margin stabilization, supported by continued investment in solar and AI initiatives. The narrative is further bolstered by Tesla’s stake in SpaceX, with anticipation building around a potential SpaceX IPO that could unlock additional shareholder value soon. However, elevated capital expenditure levels remain a key overhang, tempering investor enthusiasm despite these strategic advantages.

Serina Therapeutics (NYSE: SER, $1.88, +11%)

Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, reported (May 14) its financial results for the first quarter ended March 31, 2026, along with key business updates. The company highlighted the follow: Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 & Closed $21.2 million private placement financing to support continued advancement of SER-252. “With our Phase 1b registrational study of SER-252 now underway and a strengthened balance sheet, Serina is entering an important execution phase as we work toward our first clinical data in patients with advanced Parkinson’s disease,” said Steve Ledger, Chief Executive Officer of Serina. “SER-252 represents the first clinical validation of our POZ Platform™, which is designed to optimize well-understood therapeutics by improving pharmacokinetics, tolerability and dosing profiles. We believe this approach has the potential to unlock meaningful value across multiple modalities, and we are building a pipeline and partnership strategy to fully leverage the breadth of the platform.”

BuzzFeed, Inc. (BZFD, $1.76, +12.10%)

BuzzFeed, Inc. (NASDAQ: BZFD) has entered into a transaction agreement with Allen Family Digital, LLC, an affiliate of Byron Allen’s family office, that would see Allen invest $120 million for a majority stake in the once high-flying digital media pioneer. Under the deal, Allen’s vehicle will purchase 40 million shares at $3.00 apiece, giving it roughly 52% of BuzzFeed’s outstanding shares when the transaction closes.

FMC Corporation (NYSE: FMC, $13, +2.44%)

FMC Corporation (NYSE:FMC) reported (April 29) first quarter 2026 results above guidance with Adjusted EBITDA above high end of range, reaffirms full-year outlook. Their first quarter 2026 revenue of $759 million, down 4 percent versus first quarter 2025. First quarter 2026 revenue, excluding India, was $762 million, down 4 percent versus first quarter 2025, which included India. On a GAAP basis, the company reported a loss of $2.25 per diluted share in the first quarter, a decrease of $2.13 versus first quarter 2025. First quarter adjusted loss per diluted share of $0.23 was down 41 cents versus first quarter 2025. FMC Corporation also announced today that its board of directors declared a regular quarterly dividend of 8 cents per share (roughly 2.26%), payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.

GeoVax Labs, Inc. (GOVX, $2.75, +23.32%)

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, commented (May 20) on the rapidly evolving Bundibugyo Ebola virus (BDBV) outbreak in Central Africa and the broader implications for global infectious disease preparedness and biodefense infrastructure.

The Sources

  1. CNBC – Market Open: May 20, 2026 (real-time look at equity markets and sector moves)cnbc
    https://www.cnbc.com/video/2026/05/20/market-open-may-20-2026.html
  2. Yahoo Finance – How major US stock indexes fared Friday 5/15/2026 (context on recent index performance into mid‑May)finance.yahoo
    https://finance.yahoo.com/markets/stocks/articles/major-us-stock-indexes-fared-202242234.html
  3. Zacks Investment Research – Stock Market News for May 14, 2026 (macro, inflation data, and equity reaction)zacks
    https://www.zacks.com/stock/news/2920948/stock-market-news-for-may-14-2026
  4. Finbold – Machine learning algorithm predicts Nvidia stock price on May 31, 2026 (AI expectations and NVDA sentiment into late May)finbold
    https://finbold.com/machine-learning-algorithm-predicts-nvidia-stock-price-on-may-31-2026/
  5. Morningstar – 1 Reason Nvidia Stock Could Surge in 2026 (longer‑term AI/GPU demand backdrop)finance.yahoo
    https://finance.yahoo.com/news/1-reason-nvidia-stock-could-232300856.html
  6. SiliconData – GPU Pricing Trends 2026: What to Expect in the Year Ahead (GPU market dynamics and AI/data‑center demand)silicondata
    https://www.silicondata.com/blog/gpu-pricing-trends-2026-what-to-expect-in-the-year-ahead
  7. Gotrade – US Market Outlook May 11–15, 2026: CPI Is Key (broader macro and risk‑on/risk‑off setup into mid‑May)heygotrade
    https://www.heygotrade.com/en/news/weekly-economic-outlook-2026-05-11/

May 21, 2026

America’s Rare Earth Reckoning: From Dependency to Domestic Revival

For a nation that prides itself on independence, relying on foreign sources for more than 95% of its rare earth elements is less a strategy and more a vulnerability. These minerals—quietly embedded in everything from electric vehicles to missile guidance systems—have become the unsung protagonists of the modern economy. Yet, until recently, they have largely been someone else’s problem to produce.

That may be changing.

A Strategic Bet on American Innovation

The U.S. Department of Energy (DOE) has stepped forward with a $45.7 million investment across 19 projects aimed at strengthening domestic critical mineral supply chains. The initiative, led by the Office of Critical Minerals and Energy Innovation, is not merely a funding announcement—it is a signal that Washington sees minerals not as commodities, but as strategic assets.

The focus is clear: build pilot-scale facilities capable of processing magnesium and rare earth elements on U.S. soil. In other words, don’t just dig it up—refine it, scale it, and ultimately manufacture with it domestically.

Assistant Secretary of Energy Audrey Robertson put it succinctly: reshoring mineral production is about creating an end-to-end American supply chain. Translation for investors: less geopolitical risk, more control, and a stronger industrial base.

From Ore to Opportunity

Historically, the U.S. has not lacked geological potential. What it has lacked is infrastructure—particularly in processing and refining, where foreign players have long dominated. Mining is only the first chapter; the real value lies in what happens next.

The newly funded projects aim to rewrite that narrative through:

  • Advanced separation technologies that improve efficiency and reduce environmental impact
  • Modular processing systems that can scale more quickly than traditional facilities
  • Recycling and recovery methods that extract rare earths from electronic waste and industrial byproducts
  • Alternative feedstocks, including unconventional mineral sources that were previously uneconomical

Consider, for example, a pilot facility that extracts rare earth elements from coal ash—a legacy waste product now being reimagined as a strategic resource. It is the industrial equivalent of turning yesterday’s liabilities into tomorrow’s assets.

National Security Meets Supply Chain Strategy

The urgency behind these efforts extends beyond economics. Rare earth elements are foundational to defense systems, clean energy technologies, and advanced electronics. Dependence on foreign suppliers—particularly in geopolitically sensitive regions—introduces risks that no amount of spreadsheet modeling can fully hedge.

By investing in domestic processing capabilities, the U.S. is effectively buying an insurance policy against supply disruptions. It is also positioning itself to compete more aggressively in global markets where demand for critical minerals is expected to surge alongside electrification and decarbonization trends.

The Private Sector Angle

For investors and industry players, the DOE’s funding acts as both catalyst and validation. Early-stage technologies that might have struggled to secure capital now have a federal tailwind. This could accelerate partnerships between startups, established mining companies, and downstream manufacturers.

Moreover, the development of pilot-scale facilities suggests a near-term pathway to commercialization—a key inflection point for any emerging industrial technology.

A Measured Path Forward

While $45.7 million will not singlehandedly close the gap between U.S. demand and domestic supply, it represents a meaningful step toward diversification. More importantly, it reflects a shift in mindset: from reactive dependence to proactive development.

If successful, these initiatives could transform the U.S. from a price-taker in global mineral markets into a more self-reliant—and potentially influential—player.

And in a world increasingly defined by supply chain resilience, that is a position worth mining for.

Learn More By Watching This

The Sources

  1. U.S. Department of Energy – DOE’s Office of Critical Minerals and Energy Innovation Announces Over $45 Million to Support Domestic Critical Minerals Processing
    https://www.energy.gov/cmei/articles/does-office-critical-minerals-and-energy-innovation-announces-over-45-million-support
  2. Metal Tech News – DOE funding targets U.S. minerals processing
    https://www.metaltechnews.com/story/2026/05/20/mining-tech/doe-funding-targets-us-minerals-processing/2766.html
  3. U.S. Department of Energy – Audrey Robertson Biography
    https://www.energy.gov/cmei/person/audrey-robertson
  4. US Critical Materials – US Dependence on China for Rare Earth Elements Sparks Security Concerns
    https://uscriticalmaterials.com/us-dependence-on-china-for-rare-earth-elements-sparks-security-concerns/
  5. Econofact – Can the U.S. Reduce Its Reliance on Imported Rare Earth Elements?
    https://econofact.org/can-the-u-s-reduce-its-reliance-on-imported-rare-earth-elements
  6. Georgia Tech Research – How the US Can Mine Its Own Critical Minerals — Without Digging New Holes
    https://research.gatech.edu/how-us-can-mine-its-own-critical-minerals-without-digging-new-holes-0
  7. U.S. Department of Energy – Critical Materials Innovation Hub (CMI)
    https://www.energy.gov/cmei/ammto/critical-materials-innovation-hub-cmi
  8. U.S. Department of Energy – Developing a Domestic Supply of Critical Minerals and Materials
    https://www.energy.gov/hgeo/articles/developing-domestic-supply-critical-minerals-and-materials

May 21, 2026

AI’s Quiet Plot Twist: From Job Killer to Job Creator? -( $AMD $NOK $NVDA )

For a technology widely cast as the villain in the modern labor story, artificial intelligence may be preparing for a reputational turnaround. According to LPL Financial Chief Economist Jeffrey Roach, the narrative of mass job displacement could be missing a more nuanced—and potentially more optimistic—economic reality: AI might end up creating more jobs than it replaces.

Markets, which tend to discount both panic and euphoria with equal efficiency, are beginning to reflect that possibility—not just in theory, but in capital flows toward the companies building the AI backbone.

The Jevons Paradox Meets the Chipmakers

At the center of this shift is a familiar economic principle: the Jevons paradox, which suggests that increased efficiency often leads to increased consumption. In the AI era, that efficiency is powered by silicon.

NVIDIA has become the poster child for this dynamic. Its GPUs, once the domain of gamers, now underpin massive AI training and inference workloads. As AI becomes cheaper and more accessible, demand for compute has not plateaued—it has surged, fueling hiring across data centers, software development, and enterprise AI deployment.

Advanced Micro Devices (AMD), long cast as NVIDIA’s understudy, is capitalizing on the same structural trend. Its expanding presence in AI accelerators and data center chips reflects a broader reality: as AI lowers the cost of intelligence, companies don’t scale back—they scale up. More applications, more models, more infrastructure—each layer requiring human expertise to build, manage, and monetize.

Efficiency, in other words, is not shrinking the pie. It is enlarging it.

Networks, Not Just Nodes: Nokia’s Role in the AI Economy

If NVIDIA and AMD are supplying the computational engines, Nokia is helping ensure the data actually moves.

The Finnish telecom equipment provider, once synonymous with mobile handsets, is now deeply embedded in the infrastructure layer of the AI economy. As AI workloads grow more distributed—spanning edge computing, cloud environments, and real-time applications—network performance becomes critical.

That shift is quietly labor-positive. Expanding AI-driven networks requires engineers, operators, cybersecurity specialists, and systems architects. Nokia’s investments in 5G and next-generation network solutions position it as a less obvious, but essential, beneficiary of AI’s expansion—and, by extension, a contributor to job creation in telecom and enterprise infrastructure.

From Replacement to Reallocation

Rather than triggering widespread unemployment, AI appears more likely to reshape how work is distributed. Tasks will shift, but the total volume of work may increase.

Roach points to medical diagnostic imaging as a telling example. Lower costs have led to more scans, more facilities, and more hiring—not less. The same pattern is emerging in AI-driven industries: as tools become more powerful and accessible, usage expands.

Even within companies deploying NVIDIA or AMD hardware, or relying on Nokia’s networks, the need for human oversight remains. AI systems require training, validation, compliance checks, and strategic direction—functions that resist full automation.

A Demographic Reality Strengthens the Case

Overlay this with a shrinking labor force, and the equation changes further. LPL Financial data indicates that working-age individuals will make up roughly 62% of the population by 2050, falling below 60% by 2070.

In that environment, AI is less a job destroyer and more a force multiplier.

The rise of companies like NVIDIA and AMD reflects not just technological progress, but necessity. As fewer workers support larger economies, productivity gains become essential. AI fills that gap—not by eliminating workers, but by enabling each one to do more.

The Investment Angle: Scaling Work, Not Replacing It

For investors, the takeaway is less about which jobs disappear and more about where work expands.

NVIDIA’s valuation surge signals confidence in sustained AI demand. AMD’s momentum suggests competition will broaden the ecosystem. Nokia’s infrastructure role highlights that AI is not just about algorithms—it is about connectivity at scale.

Together, they illustrate a broader thesis: AI is not a zero-sum game for labor. It is an expansionary force that increases the volume, variety, and velocity of work.

A Future Where Work Evolves Alongside Machines

The fear that AI will hollow out the workforce is not unfounded—but it may be incomplete.

If the Jevons paradox holds, and if companies continue to deploy AI as a tool for expansion rather than contraction, the labor market could look less like a casualty and more like a beneficiary.

In that future, NVIDIA chips hum in data centers, AMD competes to democratize compute, Nokia connects the digital arteries—and somewhere in between, the number of people working does not shrink. It simply shifts, adapts, and, perhaps unexpectedly, grows.

The Sources

Here are some solid sources you can reference, in numerical order:

  1. LPL Financial – “Artificial Intelligence: The Antidote to Fed Policy” (Jeffrey Roach on AI, productivity, and demographics)
    https://www.lplmycfo.com/blog/artificial-intelligence-the-antidote-to-fed-policy[1]
  2. Glen Jackson / LPL – “Dr. Jeffrey Roach on AI’s Impact on Productivity and Inflation”
    https://www.linkedin.com/posts/glen-jackson-aif%C2%AE-723ab16_ai-productivity-boom-will-come-but-could-activity-7414279668931178[2]
  3. Jeffrey Roach, PhD – “AI Impact on Job Market: Efficiency and Demand”
    https://www.linkedin.com/posts/jeffreyroachphd_global-uncertainty-likely-to-impact-inflation-activity-7461150567428558848-lILr[3]
  4. WealthManagement – “LPL Investing in AI to ‘Prop the Advisor Up’”
    https://www.wealthmanagement.com/ibd-news/lpl-investing-ai-prop-advisor[4]
  5. Yahoo Finance / LPL – “LPL Financial Advisors Embrace AI’s Potential for Business Growth”
    https://finance.yahoo.com/news/lpl-financial-advisors-embrace-ai-130000038.html[5]
  6. CNBC – “Nvidia dominates the AI chip market, but there’s rising competition”
    https://www.cnbc.com/2024/06/02/nvidia-dominates-the-ai-chip-market-but-theres-rising-competition-.html[6]
  7. Business Insider – “Nvidia’s AI Chip Boom Could Bolster US Semiconductor Industry Jobs”
    https://www.businessinsider.com/nvidia-ai-chip-semiconductors-tsmc-intel-jobs-arizona-2024-2[7]
  8. Zacks / Yahoo – “AI-Driven Datacenter Chip Demand to Drive NVIDIA’s Q4 Earnings”
    https://finance.yahoo.com/news/ai-driven-datacenter-chip-demand-141800186.html[8]
  9. Analytics India Magazine (via LinkedIn) – “AMD announced a 4% workforce reduction to refocus on AI chip growth”
    https://www.linkedin.com/posts/analytics-india-magazine_amd-announced-a-4-workforce-reduction-to-activity-7262782530813112320-CB[9]
  10. Aura Blog – “AMD’s Workforce Realignment: Key Insights from Aura”
    https://blog.getaura.ai/amds-workforce-realignment-insights-uncovered-through-auras-analytics[10]
  11. JD Supra – “Unlocking AI’s Power to Multiply Manufacturing Productivity” (broader AI–productivity context)
    https://www.jdsupra.com/legalnews/unlocking-ai-s-power-to-multiply-5368537[11]
  12. ETF Trends – “How Nvidia Could Stoke U.S. Semiconductor Job Creation”
    https://www.etftrends.com/innovative-etfs-content-hub/nvidia-could-stoke-u-s-semiconductor-job-creation[12]

May 21, 2026

When Servers Meet SkyMiles: How SMCI, UAL and DAL Gave the S&P 500 Some Extra Lift on Wednesday -( $UAL $DAL $SMCI $CCL $NCLH $SPY )

Airlines and AI servers stole the S&P 500 spotlight today, with United Airlines (UAL), Delta Air Lines (DAL), Super Micro Computer (SMCI) and the cruise lines Carnival (CCL) and Norwegian Cruise Line (NCLH) staging the kind of synchronized rally that makes index funds look unusually clever. Under the hood, the story is a mash‑up of cheaper fuel, improving travel sentiment, and one server maker leaning hard into the AI data‑center boom.

Flight to Risk: Airlines Take the Runway

United Airlines (UAL) and Delta Air Lines (DAL) both climbed sharply today, landing among the top S&P 500 gainers as investors rotated back into cyclical travel names. United’s stock move comes against a backdrop of solid recent results but a more cautious 2026 outlook as management cited rising jet fuel costs linked to ongoing Middle East tensions.

In other words, United is posting respectable fundamentals while simultaneously warning that the industry’s biggest line item is behaving like surge pricing on a holiday weekend, a combination traders found more glass‑half‑full than half‑empty today. Delta, for its part, is busy selling the dream of a bigger transatlantic footprint in 2026, planning more than 650 weekly flights to nearly 30 European destinations next summer, including new routes from Boston to Madrid and from Seattle to Rome and Barcelona. That long‑haul ambition helped support the stock as investors looked past recent operational hiccups, including reports that the carrier canceled nearly 350 flights over a weekend due to pilot scheduling challenges.

Cruising Back Into the Conversation

Carnival Corp. (CCL) and Norwegian Cruise Line Holdings (NCLH) joined the rally, extending gains seen in recent sessions as travel‑and‑leisure names benefited from easing geopolitical jitters and softer energy prices. Recent commentary has highlighted that airlines and cruise operators, including United (UAL), Delta (DAL), Carnival (CCL) and Norwegian (NCLH), all bounced when headlines pointed to reduced tensions in the Middle East and some relief on the fuel front.

For Carnival and Norwegian, the setup is classic late‑cycle consumer risk appetite: investors are betting that passengers will keep booking cabins even as macro clouds linger, so long as oil prices cooperate and ports stay open. The cruise lines remain highly sensitive to both fuel and discretionary spending, but today’s move suggests equity markets are willing, at least for now, to pay up for the possibility of another strong peak season rather than the certainty of last year’s volatility.

Super Micro’s AI Servers Regain Altitude

Super Micro Computer (SMCI), long a proxy for AI infrastructure enthusiasm, also landed in the top S&P 500 movers after its latest earnings and guidance reset the narrative. Earlier this month, the company reported fiscal third‑quarter revenue that more than doubled year over year, even as the headline number came in shy of Wall Street estimates.

The real catalyst was forward‑looking: management guided for fourth‑quarter revenue comfortably ahead of consensus and projected adjusted earnings per share above analyst estimates as well, citing robust demand for AI‑optimized servers. That upbeat outlook sent the stock sharply higher in post‑earnings trading and helped underpin today’s strength, as investors re‑embraced the idea that Super Micro (SMCI) remains firmly embedded in the AI build‑out rather than just a momentum relic from last year’s rally.

Why Today’s Leaders Matter for the Broader Market

Taken together, today’s S&P 500 standouts reveal a market that’s willing to lean back into economically sensitive names—airlines and cruises—while still paying a premium for AI infrastructure plays. Travel operators like United (UAL), Delta (DAL), Carnival (CCL) and Norwegian (NCLH) are trading through a mix of fuel‑price uncertainty, operational wrinkles and long‑haul expansion plans, yet investors are increasingly pricing in resilient demand and a smoother 2026 travel season.

Super Micro’s (SMCI) resurgence, meanwhile, signals that AI‑linked hardware is still viewed as a structural growth story, not a passing fad, especially when management is willing to guide above the Street on both revenue and profit. For portfolio managers, today’s tape reads like a reminder that market leadership can shift quickly between “real economy” mobility and digital infrastructure—but right now, both getting people on planes and getting models onto servers are being rewarded.

The Sources

  1. United Airlines Holdings (UAL) quote and news – Yahoo Finance[1]
  2. Delta Air Lines (DAL) quote and news – Yahoo Finance[2]
  3. Super Micro Computer (SMCI) quote and news – Morningstar[3]
  4. Carnival Corp. (CCL) quote and news – Robinhood[4]
  5. Norwegian Cruise Line Holdings (NCLH) quote and news – Investing.com[5]
  6. S&P 500 overview and movers – MarketWatch U.S. Market Movers[6]
  7. Super Micro Q3 2026 earnings coverage – CNBC: Super Micro (SMCI) Q3 earnings report 2026[7]
  8. Super Micro outlook and AI server demand – Reuters: Super Micro bets on AI server demand[8]
  9. United Airlines trims 2026 outlook on fuel costs – Skift[9]
  10. United Airlines 2026 outlook and fuel costs follow‑up – Mexico Business News[10]
  11. United Airlines winter schedule expansion release – United Newsroom[11]
  12. Delta’s expanded transatlantic schedule for next summer – Delta Newsroom[12]
  13. Delta operational issues and cancellations report – People.com[13]
  14. Airline and cruise stocks rally on headlines – Facebook video: Schwab Network segment[14]
  15. General S&P 500 gainers snapshot – Slickcharts Market Movers[15]

May 20, 2026

Stifel Places Target On Eupraxia During National Eosinophil Awareness Week -( $EPRX $SNY $REGN $TAK )

Stifel just initiated coverage during National Eosinophil Awareness Week on Eupraxia Pharmaceuticals (EPRX) with a Buy rating and a 25 dollar price target—roughly four times where the stock changed hands around the report—on the view that a sleepy drug‑delivery story is about to wake up GI and osteoarthritis markets. That bullish stance rests on Diffusphere, a platform that turns a well‑worn steroid into a once‑yearly esophageal tune‑up and, potentially, a franchise that extends across the GI tract, EOE, and into the knee.

A precision platform hiding in plain sight

Eupraxia is a clinical‑stage biotech built around Diffusphere, a polymer‑coated microparticle system designed to keep familiar drugs exactly where physicians want them, and for far longer than standard formulations allow. The platform’s lead embodiment, EP‑104GI, repackages fluticasone propionate—a workhorse steroid that has seen more clinics than most junior residents—into a long‑acting injectable for gastrointestinal disease, starting with eosinophilic esophagitis (EoE).

Unlike conventional extended‑release technologies that can dump drug into the bloodstream or fade too quickly, Diffusphere particles are engineered to sit in the injected tissue and leak fluticasone at a near‑constant rate for up to a year, keeping systemic exposure well below the levels seen with inhaled fluticasone. In Phase 1b/2a, plasma cortisol and glucose curves were reassuringly flat and stayed within normal ranges over 52 weeks, suggesting the esophagus is doing the work while the adrenal glands get the year off.

EoE: a growing market with a compliance problem

EoE has quietly evolved from a rare curiosity into a mainstream GI diagnosis, with Stifel modeling roughly 1 million U.S. patients by 2030 as awareness and endoscopy rates rise. Even after proton pump inhibitors and dietary interventions, about half of this population remains uncontrolled, implying hundreds of thousands of patients who still struggle with dysphagia, pain, and the occasional memorable encounter with a steak lodged mid‑chest.

Therapy has historically oscillated between swallowed steroids and biologics, both effective but limited by either short duration or high cost and chronic administration. Takeda’s (TAK) FDA approved Eohilia, a budesonide oral suspension, delivers 12 weeks of treatment at 2 mg twice daily, achieving histologic remission in just over half of treated patients but with notable rates of oral candidiasis and adrenal suppression in trials. Dupixent—co‑owned and co‑promoted by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN)—has set the high bar on efficacy and durability with weekly injections, including up to 52‑week histologic remission in most patients, but at biologic‑grade pricing, injection‑site reactions, and the expectation of ongoing dosing.

One scope, twenty shots, fifty‑two weeks

Eupraxia’s EP‑104GI proposes a different deal: one endoscopy, 20 submucosal injections spaced like clock‑face coordinates up the esophagus, and potentially a year of local steroid exposure with minimal systemic baggage. In the Phase 1b/2a RESOLVE trial, higher‑dose cohorts (20 injections of 6–8 mg each) delivered a roughly 65 percent mean reduction in the EREFS endoscopic severity score at week 12 for patients with baseline scores above 2, with near‑complete resolution in the top‑dose group.

Those structural gains matched up with histology and symptoms in a way that’s unusual enough to get GI specialists’ attention. Peak eosinophil counts fell by about 70 percent in the highest‑dose cohort by week 36, with around two‑thirds of biopsies crossing the conventional remission threshold of fewer than 6 eosinophils per high‑power field. Clinically, roughly 60 percent of patients across mid‑ to high‑dose cohorts reached remission on the Straumann Dysphagia Instrument and maintained it out to week 52, with higher doses hitting the accepted “remission” change of at least 3 points more quickly.

The safety profile reads like a steroid formulation trying very hard not to behave like a steroid: no meaningful trends in cortisol suppression, no hyperglycemia signal, no oral thrush, and no serious adverse events attributed to EP‑104GI. Most procedure‑related issues were what one would expect when poking an esophagus 20 times with a needle—transient and self‑limited—raising the possibility that the biggest barrier is psychology, not pharmacology.

Competing with Eohilia and Dupixent on time, not molecules

Stacked against the current EoE armamentarium, Eupraxia’s differentiation is less about what’s in the syringe and more about when and where it goes. Eohilia depends on twice‑daily adherence over 12 weeks, exposes the entire esophagus and oropharynx, and needs to be cycled or repeated in a disease that is chronic by nature. Dupixent, from Sanofi and Regeneron, delivers potent systemic IL‑4/IL‑13 blockade and strong histological responses over 24–52 weeks, but requires ongoing subcutaneous injections and carries the usual biologic expense.

EP‑104GI’s pitch is essentially, “treat once, check annually.” The single‑procedure paradigm aligns neatly with what guidelines and payers already want: yearly endoscopic surveillance in symptomatic EoE, with therapy delivered at the same time rather than in a separate chronic regimen that patients might abandon once they feel marginally better. In the mid‑dose and high‑dose cohorts, 9‑ to 12‑month data suggest sustained structural and symptom improvement off a single injection sequence, putting EP‑104GI in its own category on durability even before head‑to‑head comparisons.

From a pure efficacy perspective, Dupixent’s Phase 3 program remains the gold standard, with high rates of patients achieving histologic thresholds at 52 weeks in some regimens. But EP‑104GI’s emerging data show remission rates and eosinophil reductions that are directionally competitive for a localized steroid, particularly at the highest doses—without the systemic immunomodulation. That trade‑off may resonate with patients who are more comfortable experimenting with a high‑tech steroid shot than committing to years of biologic therapy for a condition they didn’t know existed five minutes before their first scope.

Follow the money: why GI docs may quietly cheer

For gastroenterologists, the EP‑104GI model checks several practical boxes that traditional EoE therapy does not. Annual endoscopy is already embedded in practice patterns, and adding a submucosal injection sequence during the same procedure adds 30–40 minutes but opens the door to separate billing for both the scope and drug administration. Stifel notes that existing procedure codes and buy‑and‑bill economics could translate into roughly 30–40 percent higher reimbursement for physicians relative to simply writing a prescription, a change that might make the injection count feel more like a feature than a burden.

More importantly, the “one‑and‑done‑for‑now” approach almost guarantees follow‑up: patients must return for the next annual treatment/endoscopy, rather than drifting away on self‑administered biologics and skipping recommended surveillance once they feel better. That loop is attractive for both quality of care and revenue continuity in EoE, a field where under‑diagnosis and under‑monitoring have been persistent themes even as prevalence rises.

On pricing, Stifel assumes an annual WAC around 45,000 dollars for EP‑104GI in the U.S., between Eohilia’s mid‑five‑figure course and Dupixent’s six‑figure annual cost, which still leaves room for attractive margins while offering payers a year‑long solution at a discount to systemic biologic therapy. With net pricing modeled lower after discounts and a modest royalty to formulation partner Auritec, the firm forecasts probability‑adjusted peak U.S. revenues of about 1.4 billion dollars from EoE alone by 2040, plus incremental contribution from Europe.

Beyond EoE: turning strictures into a second act

If EoE is the opening chapter, benign esophageal strictures are the natural sequel. These fibrotic narrowings often arise from reflux disease, EoE itself, or prior surgery, and they are managed primarily through balloon dilations that are as unsatisfying long term as they sound. Roughly two‑thirds of patients require repeat dilations within a year, creating a cycle of tissue injury and scarring that keeps endoscopy suites busy but does little to reassure patients.

Short‑acting steroid injections are already used in some centers post‑dilation, and meta‑analyses suggest a roughly 55 percent relative reduction in restenosis—but the effect is constrained by the drug’s short half‑life at the lesion site. EP‑104GI’s data in EoE on structural reversal—improved EREFS scores, reductions in histologic fibrosis, and sustained eosinophil control—make long‑acting steroid delivery at stricture sites a conceptually tidy extension.

Stifel models a Phase 2b start in benign esophageal strictures, assigns a conservative 30 percent probability of success at this early stage, and still arrives at roughly 835 million dollars in probability‑adjusted peak sales by 2040 based on about 20 percent penetration of eligible U.S. and EU procedures. Layered on top of EoE, those numbers begin to resemble a “pipeline‑in‑a‑product” story where one carefully tuned formulation supports multiple GI indications with similar procedure‑based workflows.

Platform optionality: knees today, more organs tomorrow

EP‑104GI is not Diffusphere’s only claim on future cash flows. Eupraxia has already run a Phase 2b trial (SPRINGBOARD) of EP‑104IAR, an intra‑articular fluticasone formulation for knee osteoarthritis, which met its primary endpoints and is now parked in the “ready for partnership” bucket for Phase 3. While the osteoarthritis opportunity is sizable, Stifel’s valuation focus remains on the GI franchise, with EP‑104IAR treated more as upside optionality pending a commercial partnership that can shoulder large musculoskeletal trials.

Under the hood, the platform has been tested with a variety of active ingredients—from chemotherapeutics to anti‑infectives—suggesting that Diffusphere could support additional local delivery programs in oncology, infectious disease, or pain if capital and partners line up. Intellectual property protection rests on the altered crystal formulations, methods of use by indication, and manufacturing know‑how, giving Eupraxia multiple levers to defend territory beyond the basic fluticasone patents.

Valuation and what has to go right

Stifel’s 25 dollar target blends a discounted cash‑flow model (15 percent WACC, 1 percent terminal growth) with a sum‑of‑the‑parts analysis that risk‑adjusts the EoE and stricture opportunities to 60 percent and around 25–30 percent probabilities of success, respectively. The math assumes EP‑104GI reaches the EoE market around 2030, eventually treating close to 60,000 U.S. patients annually at 20 percent penetration of the uncontrolled, diagnosed population, and building EU5 sales off a discounted price base.

Cash on the balance sheet—about 139 million dollars with no debt at the time of the initiation—provides runway through near‑term catalysts, but longer‑term development across multiple indications will almost certainly require fresh capital or partnerships. If everything works, Stifel’s DCF and SOTP both cluster in the mid‑20s per share, leaving current levels looking, in their view, like a relatively de‑risked entry point for a drug‑delivery story with real commercial teeth.

Risks: clinical, competitive, and the 20‑needle question

As with any small‑cap biotech, the biggest near‑term risk is binary: the Phase 2b RESOLVE readout in EoE, expected in the fourth quarter of 2026, needs to replicate or exceed Phase 1b/2a signals on histology, endoscopy, and symptoms in a randomized, placebo‑controlled setting. A miss on dose selection, placebo response, or an unexpected safety signal could force a reset of the entire GI narrative, not just delay it.

Competition in EoE is also intensifying faster than the average esophagus can scar. Eohilia from Takeda gives community gastroenterologists an oral steroid they know how to write for, while Dupixent from Sanofi and Regeneron is steadily building real‑world evidence and guideline support as a biologic standard. Any safety surprises, payer pushback on procedure‑plus‑drug economics, or patient resistance to the idea of “20 esophageal injections” could slow Diffusphere’s uptake even if the data are solid.

Finally, platform expansion is optional, not guaranteed. Benign esophageal strictures and Crohn’s‑related strictures are large but complex markets, where trial design, recruitment, and endpoints will matter as much as pharmacology. Osteoarthritis, for its part, lives in a crowded, generic‑friendly world; here, Eupraxia’s success may depend less on the elegance of Diffusphere and more on the quality of any commercial partner willing to write the bigger checks.

World Eosinophilic Esophagitis Day – May 22

The EoE Day Alliance, is proud to launch World Eosinophilic Esophagitis Day (#EoEDay) a global awareness day dedicated to shining a light on Eosinophilic Esophagitis (EoE), a chronic and often underdiagnosed immune condition.

Taking place on May 22, 2026, this important milestone brings together patient organizations from around the world including Austria, Brazil, Spain, the USA, Australia, the UK, Italy, Switzerland, Israel, and Serbia, all working together to:

  • Raise awareness of EoE and its symptoms
  • Encourage people to seek medical advice for signs like difficulty swallowing or persistent reflux
  • Advocate for better care, research, and access to treatment, especially in under-resourced countries
  • Promote the Global EoE Patient Care Path that our alliance created together

Life Narrows – An EOE Day Alliance Film (EoE Doesn’t Kill. But Life Narrows)

The Sources

  1. Stifel initiation report on Eupraxia Pharmaceuticals (EPRX), “Precise Platform with Easy‑to‑Swallow Value Creation,” May 20, 2026.
  2. Eupraxia Pharmaceuticals – RESOLVE Phase 1b/2a EP‑104GI EoE data (conference/academic poster and related disclosures).eupraxiapharma+1
  3. Eupraxia Pharmaceuticals press and SEC‑style disclosures summarizing EREFS and other EP‑104GI efficacy data in EoE.prnewswire+1
  4. Patient‑oriented and trade coverage of EP‑104GI performance in EoE, summarizing trial readouts.patientworthy
  5. FDA approval information and medical‑society summaries for Eohilia (budesonide oral suspension) in EoE, including efficacy and safety profile.globalgenes+2
  6. Clinical and real‑world data on Dupixent (dupilumab) in EoE, including long‑term efficacy and safety, as well as sponsor disclosures from Sanofi (SNY) and Regeneron (REGN).gi+3
  7. Background clinical resources on EoE epidemiology, diagnostic criteria (including EREFS and histologic thresholds), and standard‑of‑care management.libguides.reading+1
  8. Corporate and event materials describing Eupraxia’s Diffusphere technology, pipeline, and KOL‑focused discussions of EP‑104GI.lapal.medicinespatentpool+1
May 20, 2026

SPCX Ready for Liftoff: Why the SpaceX IPO Could Redefine ‘Blue-Chip’ in Orbit -( $GS $SAR $SPCX $TSLA )

SpaceX’s long-awaited leap to the public markets is finally underway, and Wall Street is treating it less like a traditional IPO and more like the financial equivalent of a rocket launch countdown. With a Nasdaq listing planned under the ticker “SPCX,” Elon Musk is about to test investor appetite for a rare mix of rockets, satellites and artificial intelligence in a single equity story.

A Market Debut Decades in the Making

SpaceX is moving to flip its IPO documents into the public domain as early as late May, setting up a June marketing blitz, June 11 pricing and a potential June 12 Nasdaq debut, according to multiple reports. The listing, which follows a confidential SEC filing earlier this year, would give public investors first direct access to one of the most closely watched private companies of the past two decades.

The company is reportedly targeting as much as 75 billion dollars in IPO proceeds at a valuation north of 2 trillion dollars, a level that would make the offering the largest in history by deal size and implied market cap. That scale puts SpaceX in a different orbit from even Saudi Aramco’s (SAR) 2019 debut, which raised about 29 billion dollars.

Why “SPCX” Matters for Nasdaq

SpaceX has chosen Nasdaq as its listing venue and will trade under the ticker symbol “SPCX,” a four-letter code that has been quietly cleared in anticipation of the deal. A fund manager recently relinquished the symbol, effectively rolling out the red carpet for Musk’s company.

For Nasdaq, landing SpaceX is a marquee win in the perennial duel with the New York Stock Exchange for high-profile tech and growth listings. For index providers and ETF sponsors, “SPCX” is likely to become compulsory real estate in future space, AI and disruptive innovation products almost as soon as the stock is seasoned.

From Underdog to Space Infrastructure Giant

SpaceX has evolved from a scrappy upstart into what amounts to critical infrastructure for the U.S. space program and a growing number of commercial customers. Its launch business now commands a dominant share of the global market, fueled by the reusable Falcon rockets and the development of the heavy-lift Starship system.

The company holds billions of dollars in government contracts and has become the go-to launch provider for both NASA and private satellite operators, shrinking lead times and cost per kilogram to orbit. In practical terms, SpaceX turned what was once a rare national event—launch day—into something closer to a regular programming slot.

If the rockets provide the spectacle, Starlink provides the cash flow. SpaceX’s satellite broadband arm operates the largest constellation of satellites in low Earth orbit, offering high-speed internet service from rural communities to conflict zones.

Analysts estimate that the launch and Starlink businesses together are approaching roughly 20 billion dollars in revenue in 2026, making them the financial backbone of the SpaceX story heading into the IPO. That level of scale helps explain how the company can credibly pursue both ambitious infrastructure buildouts and capital-intensive deep-space projects while still talking about a public listing that investors can model.

The AI Angle: Grok Joins the Flight Manifest

Adding a modern twist, SpaceX also owns the Grok AI assistant, acquired in an all-stock deal when Musk’s xAI was folded into the company earlier this year. While Grok’s expected revenue contribution is modest—likely less than 1 billion dollars near term—it gives SpaceX exposure to one of the hottest themes in the public market: generative AI.

The combined narrative of a space-and-AI platform ties neatly into Musk’s broader pitch of building infrastructure for a multiplanetary future while monetizing data, connectivity and intelligence in the present. It also gives equity analysts something familiar to anchor on, even as they navigate discounted cash flow models that include rockets, satellites and neural networks in the same spreadsheet.

Bankers, Roadshows and a Very Crowded Room

On the banking side, SpaceX has assembled a who’s who of Wall Street, including Bank of America, Citigroup, Goldman Sachs (GS), JPMorgan and Morgan Stanley in senior underwriting roles. Additional firms have been added further down the roster, reflecting the scale of both the deal size and investor demand.

A formal roadshow is expected to begin in early June, with executives fanning out—physically and virtually—to court institutional capital ahead of the June pricing date. Given the profile of the issuer and the scarcity of comparable public names, the bigger challenge for underwriters may be managing allocations than stoking interest.

Record-Breaking Aspirations and Valuation Gravity

Valuing SpaceX at more than 2 trillion dollars puts it in the same conversation as the largest technology platforms on earth, despite operating hardware-intensive businesses that historically have traded at lower multiples. Supporters argue that the combination of recurring Starlink revenue, high barriers to entry and potential AI upside justifies a premium more akin to a dominant cloud and data platform than a traditional aerospace contractor.

Skeptics, for their part, will likely focus on capital intensity, regulatory risk and the long timelines associated with deep-space projects that generate more headlines than near-term free cash flow. As always in growth stories, gravity eventually shows up in the form of quarterly earnings, but for now the narrative is operating comfortably in orbit.

Retail Investors Eye the Launch Pad

Retail investors who have watched SpaceX’s rise from the sidelines are already gaming out how to get a seat on the mission. Once the Nasdaq debut occurs, buying shares will be as straightforward as opening or funding a brokerage account with access to U.S. markets and entering the “SPCX” ticker, though early trading could be volatile given expected demand.

Until the listing is complete, SpaceX remains a private company, meaning there is no direct access to the shares on public exchanges, aside from limited secondary-market transactions for accredited investors. The IPO effectively turns what was once the domain of venture funds and private secondary desks into a liquid security that can sit next to megacap tech names in portfolios.

The Bigger Question: What Comes After Liftoff?

Beyond the day-one pop, the more interesting question may be how public ownership influences SpaceX’s next chapter. Public markets reward execution, visibility and discipline; Musk’s companies, historically, have specialized more in audacious timelines and radical ambition.

If SpaceX can translate its private-market track record into consistent public-market performance, SPCX could become a bellwether for a new class of “infrastructure-tech” companies that blend hard assets, software and AI. And if not, investors at least will have had front-row seats to one of the most fascinating experiments in turning science fiction into GAAP financials.

Learn More Here

The Sources

  1. Reuters – “Exclusive: SpaceX accelerates IPO timeline, targets June 12 listing on Nasdaq”
    https://www.reuters.com/world/spacex-accelerates-ipo-timeline-targets-june-11-pricing-nasdaq-2026-05-15/reuters
  2. Fortune – “SpaceX said to plan public IPO filing as soon as Wednesday”
    https://fortune.com/2026/05/15/spacex-ipo-public-filing-elon-musk-trading-debut-ticker-spcx/fortune
  3. Bloomberg – SpaceX IPO / Nasdaq listing coverage (homepage link; article-level link may require subscription)
    https://www.bloomberg.combloomberg
  4. Yahoo Finance – “Exclusive: SpaceX accelerates IPO timeline, targets June 12 listing on Nasdaq” (syndicated)
    https://finance.yahoo.com/markets/stocks/articles/exclusive-spacex-accelerates-ipo-timeline-194800007.htmlfinance.yahoo
  5. Stake – “SpaceX IPO: How to buy SpaceX shares?”
    https://hellostake.com/au/blog/trending/how-to-invest-in-spacex-stockhellostake
  6. YouTube – “SpaceX Files For IPO – Here’s What To Know”
    https://www.youtube.com/watch?v=gq0-6U_bQbQyoutube
  7. Forge Global – “Invest and Sell SpaceX Stock” (private-market background)
    https://forgeglobal.com/spacex_stock/forgeglobal

Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here

Copyright © 2026 Vista Partners, LLC. All rights reserved